Featured Content

Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations

Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for ...

Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib

In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic imatinib at a higher frequency compared with those given brand-name ...

Opinion: Understanding the FDA's Take on Cannabidiol

In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.

Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing

"People have shown that the variant-identification quality of WGS is superior to WES," said Dr Gerstein.

Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves

Patient-reported outcomes, or PROs, are going to play a larger role in FDA cancer drug approvals, according to an expert in the field.

More Features>>>

Chronic Myeloid Leukemia Resources

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs